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Factors related to good asthma control using different medical
adherence scales in Latvian asthma patients: an observational
study
Dins Smits 1, Girts Brigis1, Jana Pavare2, Baiba Maurina3 and Noël Christopher Barengo4
One of the main challenges in asthma control is adherence to pharmaceutical treatment. The aim of this study was to test the
association between adherence to asthma medication, control and medical beliefs, cognitive and emotional perceptions using
three different validated questionnaires. Beliefs about asthma medicine, cognitive and emotional factors were determined in a
cross-sectional survey of patients attending outpatient pulmonologist practices in Latvia (n = 352). The validated Beliefs about
Medicines Questionnaire and the Brief Illness Perception Questionnaire were used. Adherence to asthma medication was assessed
using the Morisky Medication Adherence Scale and two different versions of the Medication Adherence Reporting Scale. Several
questions about necessity or concerns related to pharmaceutical treatment were able to predict poor adherence according to the
Morisky scale. If the patient felt that without the asthma medication his life would be impossible, his risk to have poor treatment
adherence was 46% reduced (odds ratio 0.54; 95% confidence interval 0.33–0.89). Furthermore, asthma patients who were
convinced that their health depends on the asthma treatment were less likely to have poor treatment adherence (odds ratio 0.56:
95% confidence interval 0.32–0.97). In case the patient was concerned by the need to constantly use asthma medication or
sometimes concerned by long-term effects of asthma medication the odds of poor treatment adherence were 1.96 (95%
confidence interval 1.19–3.24) and 2.43 (95% confidence interval 1.45–4.08), respectively. In conclusion, medication beliefs,
particularly concerns and necessity of asthma treatment were associated with poor treatment adherence when assessed with the
Morisky or 5-item Medication Adherence Reporting Scale.
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INTRODUCTION
Asthma is a serious global health problem affecting approximately
300 million people worldwide.1, 2 The estimated prevalence of
people living with asthma ranges from 1 to 21% in adults and with
up to 20% of children aged 6–7 years experiencing severe
wheezing episodes within a year.3, 4
One of the main challenges in asthma control is adherence to
pharmaceutical treatment. Generally, poor adherence is common
across many chronic diseases such as asthma.5, 6 As it is not easy
to test clinically for adherence, several questionnaires have been
developed to assess adherence to medication.7, 8 These ques-
tionnaires are widely used in many countries. However, no
information is available on treatment adherence of asthma
patients in Latvia.
Several factors influence treatment adherence. Some of these
factors are related to complexity of the therapy, fear of side effects
of drugs, method of taking the drug, dosage regimen, adverse
events, knowledge about the essence of the disease and its
complications, illness perception and social support.6, 9, 10
Especially, medical beliefs, cognitive and emotional perceptions
have shown to be related to medical adherence.11, 12 Furthermore,
individual asthma management might be improved by a better
understanding of the types of beliefs or illness-related perceptions
that are associated with low adherence to preventer medication.13
Vrijens et al.’s proposed Ascertaining Barriers to Compliance (ABC)
taxonomy conceptualizes adherence to medications in line with
principles of behavioral and pharmacological science.14 The ABC
taxonomy defines the overarching concept of “medication
adherence” as the process by which patients take their medication
as prescribed and subdivides it into 3 essential elements: (A)
initiation; (B) implementation, and (C) persistence. This subdivision
outlines the sequence of events that have to occur for a patient to
experience the optimal benefit from his or her prescribed
treatment regimen.14
Thus, comparing how well these factors predict treatment
adherence in the currently available adherence scores, may give
valuable insight in the questionnaire-of-choice for the Latvian
asthma population in order to be implemented in clinical practice
throughout the country.
The aim of this study was to test the association between
adherence to asthma medication, control and medical beliefs,
cognitive and emotional perceptions using three different
validated questionnaires in Latvian asthma patients.
RESULTS
The baseline characteristics of the study population are presented
in Table 1.
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The majority of the patients had professional education and
were earning at least 300 euros per month. Two out of three
patients were using corticosteroids and one third a combination
therapy consisting of corticosteroids and a beta 2 mimetic drug.
The prevalence of poor asthma control was 63% in men and 66%
in women. The prevalence of poor treatment adherence ranged
between 58–76% in men and 69% in women. Age, income, and
education were statistically significantly differently distributed
between men and women.
Table 2 shows the associations of the different asthma
medication adherence scores with poor asthma control in the
study sample. None of the three adherence scores was able to
predict poor disease control in Latvian asthma patients.
None of the socio-demographic or socio-economic factors were
predictors of poor treatment adherence according to the Morisky
or the MARS 10-item scale (Table 3). Further adjustment did not
change the findings of the unadjusted model.
However, when the Medication Adherence Reporting Scale
(MARS) 5-item scale was used, increasing age (odds ratio (OR) 0.98
(95% confidence interval (CI) 0.97–1.00) and monotherapy with
corticosteroids (OR 0.57; 95% CI 0.35–0.91) reduced the odds of
poor treatment adherence. Moreover, professional education level
(OR 1.79; 95% CI 1.03–3.11) or the combined use of corticosteroids
and beta 2 mimetics (OR 1.93; 95% CI 1.18–3.16) increased the
odds of poor treatment adherence.
The associations of cognitive and emotional illness indicators
and poor treatment adherence measured using three different
scores in asthma patients in Latvia are presented in Table 4. None
of the eight items of the brief Illness Perception Questionnaire
(Brief IPQ) was a statistically significant predictor of poor
treatment adherence in any of the three adherence scores.
Adjustment for age, education or income did not alter the results.
Whereas beliefs about medication were not associated with
poor treatment adherence on the MARS 10-item scale, several
questions about necessity or concerns related to pharmaceutical
treatment were able to predict poor adherence according to the
Morisky scale (Table 5).
If the patient felt that without his asthma medication his/her life
would be impossible, his risk to have poor treatment adherence
was 46% reduced (OR 0.54; 95% CI 0.33–0.89). Furthermore,
asthma patients who were convinced that their health depends
on the asthma treatment were less likely to have poor treatment
adherence (OR 0.56: 95% CI 0.32–0.97). Each of the three concerns
about medication questions was a statistically significant predictor
of poor treatment adherence. In case the patient was concerned
by the need to constantly use asthma medication or sometimes
concerned by long-term effects of their asthma medication the
odds of poor treatment adherence were 1.96 (95% CI 1.19–3.24)
and 2.43 (95% CI 1.45–4.08), respectively. Furthermore, patients
who felt that their asthma medication is incomprehensible to
them had a two-fold increase in risk of poor treatment adherence.
In regard MARS 5-item scale, only two variables were able to
predict poor treatment adherence. The risk of poor adherence was
58% reduced (95% CI 0.24–0.74) if the patients felt that their
future health depends on their asthma medication. In addition,
concerns about long-term effects of asthma medication increased
the risk of poor treatment adherence two-fold (95% CI 1.22–3.27).
DISCUSSION
Main findings
This study found that socio-economic, socio-demographic or
illness perceptions were not associated with poor asthma
treatment adherence in Latvia patients. However, we revealed
that concerns about the use of asthma medication and several
beliefs about the necessity of asthma medication were able to
predict poor treatment adherence when assessed by the Morisky
or MARS 5-item adherence scales. Finally, the high prevalence of
poor asthma control and treatment adherence in Latvian asthma
patients is a great concern.
Interpretation of findings in relation to previously published work
Our findings revealing that two out of three Latvian asthma
patients have poor disease control are in line with previous
Table 1. Baseline characteristics of the study sample
Men Women Total
(n= 85) (n= 264) (n= 352) p-value
Age, mean (SD) 53.7 (17.4) 58.7 (16.6) 57.5 (16.9) 0.017
Education, % 0.006
Basic 3.5 7.5 6.5
Secondary 23.3 27.1 26.1
Professional 47.7 28.9 33.5
Higher 25.6 36.5 33.8
Income, % 0.005
<300 €/month 16.7 25.3 23.2
300–550 €/month 36.9 48.2 45.5
550–750 €/month 28.6 18.3 20.8
>750 €/month 17.9 8.2 10.6
Asthma medication, %
Corticosteroids 62.8 63.4 63.3 1.00
Corticosteriods + beta
2 mimetic
33.7 33.2 33.3 1.00
Poor asthma control, % 62,8 66 65,3 0.604
Poor treatment adherence, %
Morisky scale 72.1 69.4 70.1 0.686
MARS (5-item) scale 58.1 68.7 66.1 0.089
MARS (10-item) scale 75.6 69 70.6 0.278
Table 2. Associations of different asthma medication adherence
scores with poor asthma control
Univariate Multivariatea
OR (95% CI) OR (95% CI)
Men
MARS (5-item) 0.39 (0.15–1.00) 0.36 (0.12–1.09)
MARS (10-item) 1.05 (0.38–2.90) 1.41 (0.43–4.65)
Morisky 1.02 (0.38–2.69) 1.48 (0.49–4.50)
Women
MARS (5-item) 1.04 (0.60–1.79) 1.2 (0.67–2.17)
MARS (10-item) 1.68 (0.98–2.87) 1.61 (0.91–2.86)
Morisky 1.09 (0.63–1.89) 0.94 (0.52–1.70)
All
MARS (5-item) 0.81 (0.51–1.30) 0.87 (0.52–1.44)
MARS (10-item) 1.5 (0.93–2.40) 1.43 (0.87–2.36)
Morisky 1.07 (0.67–1.72) 0.99 (0.60–1.66)
>6 (MARS-5),>14 (MARS-10),>1 (MMAS) was used to define poor medical
adherence; ≤19 for the ACT was defined to indicate poorly controlled
asthma
OR odds ratio, CI confidence interval
a Adjusted for age, education and income
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findings indicating a prevalence of 49–76% of poor asthma control
in the European population.14–18 Furthermore, good asthma
control seemed to be more difficult to achieve in asthmatic
adults who had used corticosteroids (ICS) in the last 12 months
compared with those who were not in need of inhaled
corticosteroids.15 The three treatment adherence scales used in
this study revealed that close to seven out of ten asthma patients
in Latvia have poor treatment adherence. Unlike poor asthma
control, the prevalence of poor adherence in Latvian is
considerably higher than reported in other European patient
populations.19–21 For instance, poor adherence to asthma
medication was found to be between 30–40% in France, Germany,
and Italy.19
The health belief model tries to explain how beliefs about
medicines affect ones behavior to take medication proposing that
a patient chooses a certain behavior through a cost-benefit
analysis where the perceived benefits such as health improve-
ments are compared against the perceived costs.22, 23 Unclear
results have been published about whether necessity, concerns
and the necessity-concern differential correlate with adherence in
asthma patients.24–27 In contrast to our results, some studies
assessing the associations of necessity, concerns and medication
adherence in asthma patients revealed that only necessity beliefs
were associated to medication adherence.24, 25
Byer et al. found that self-reported adherence was significantly
positively correlated with the necessity in 64 asthma patients were
from a general practice in Leicester, UK.24 In addition, unlike our
results they also reported a correlation between illness perception
and medical adherence. Another study in 93 patients aged 18–80
years who filled at least two ICS prescriptions showed that
necessities were positively related to self-reported adherence
suggesting that it could be more important to focus on necessities
than on concerns in an attempt to improve adherence.25 In line
with our results, other studies Menckeberg et al. showed a positive
relationship between the necessity-concerns differential and
adherence indicating that having stronger beliefs about the
necessity of treatment compared to concerns about negative
consequences may increase adherence.26, 27
A possible explanation of the contradictory results may be
related to the power of the study. Most of the previous studies
had a much lower sample size lacking power to detect an
association between concerns and medical adherence given that
most likely the association between necessity and medical
adherence may be stronger than for concerns and adherence. A
recent meta-analysis suggested that necessity and concern beliefs
about medicines are one important factor to consider when
understanding reasons for non-adherence in chronic disease
patients.28 Furthermore, they highlighted that the effect size for
necessity was stronger in asthma and weaker in the cardiovascular
group compared to the overall effect size. However, this may also
reflect the difference in symptomatic vs. asymptomatic conditions
of the diseases. An earlier meta-analysis by Horne et al. found a
statistical significant association between necessity and concern
beliefs and medication adherence even when stratified by
country, sample size and type of adherence measure used.29
It was of surprise that the combined use of corticosteroids and
beta 2 mimetics using the MARS (5-item) showed a lower
adherence than corticosteroids as it would have been expected
that the clinical effect of combination therapy would favor
adherence. As this finding was only observed in the MARS (5-
item) and not in the Morisky Medication Adherence Scale (MMAS)
or MARS (1-item), we hypothesize that the MARS (5-item) may be
confounded by the additional elements/dimensions included in
the other two scales.
There are many self-report scales for measuring medication
adherence. Due to the different nature of the diseases, there is no
gold standard scale for measuring medication adherence.30 Our
study showed the best associations between the necessity-
concern framework with the Morisky scale but not with the MARS
scale. The MARS scale has revealed adequate reliability but its
validity seems to be only moderate-weak.30, 31 It has been
suggested that though the internal consistency of the MARS could
be improved either by adding more response options or by
adding more items, it is debatable whether this would constitute
an improvement to the measure, or whether it would compromise
its quick, simple format.30 According to our results, we suggest to
Table 3. Associations of socio-demographic and socio-economic factors with poor treatment adherence in asthma patients
Morisky scale MARS (5-item) MARS (10-item)
Unadjusted Adjusteda Unadjusted Adjusted Unadjusted Adjusted
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age 1 (0.98–1.01) 1 (0.98–1.01) 0.98 (0.97–1.00) 0.98 (0.96–0.99) 1 (0.99–1.02) 1 (0.98–1.01)
Female sex 0.88 (0.51–1.50) 0.86 (0.48–1.54) 1.58 (0.96–2.60) 1.87 (1.07–3.27) 0.72 (0.41–1.26) 0.65 (0.35–1.18)
Education
Basic or secondary 1 Refb 1 Ref 1 Ref 1 Ref 1 Ref 1 Ref
Professional 1.43 (0.82–2.51) 1.55 (0.86–2.78) 1.79 (1.03–3.11) 1.91 (01.05–3.45) 1.23 (0.69–2.17) 1.15 (0.63–2.08)
Higher 1.45 (0.83–2.53) 1.72 (0.92–3.22) 1.27 (0.75–2.16) 1.25 (0.68–2.29) 0.97 (0.56–1.69) 1.16 (0.62–2.17)
Income
<300 €/month 1 Ref 1 Ref 1 Ref 1 Ref 1 Ref 1 Ref
300–550 €/month 0.83 (0.45–1.52) 0.74 (0.40–1.38) 0.86 (0.48–1.55) 0.89 (0.48–1.65) 0.86 (0.46–1.58) 0.81 (0.43–1.53)
550–750 €/month 0.67 (0.33–1.34) 0.51 (0.24–1.09) 0.8 (0.41–1.59) 0.66 (0.31–1.43) 0.62 (0.31–1.26) 0.54 (0.25–1.17)
>750 €/month 1.27 (0.50–3.22) 0.92 (0.33–2.54) 0.87 (0.38–2.03) 0.75 (0.29–1.93) 0.77 (0.32–1.84) 0.64 (0.25–1.69)
Asthma medication
Corticosteroids 1.34 (0.83–2.16) 0.82 (0.49–1.36) 0.57 (0.35–0.91) 0.56 (0.33–0.93) 0.69 (0.42–1.12) 0.72 (0.43–1.21)
Corticosteriods + beta 2 mimetic 1.04 (0.64–1.69) 0.85 (0.51–1.41) 1.93 (1.18–3.16) 2.04 (1.19–3.49) 1.18 (0.72–1.93) 1.11 (0.66–1.86)
OR odds ratio, CI confidence interval
a Adjusted for age, sex, education and income
b Reference group
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use the Morisky scale in Latvian asthma patients as a tool to assess
medical adherence.
Strengths and limitations of this study
Our study had several limitations that need to be considered.
Asthma medication adherence was measured by self-report
questionnaires not previously validated in the Latvian population.
Even though the MMAS and the MARS 10-item scales have been
successfully validated in other studies,32–35 self-reported measure-
ments of medication adherence may not be that precise and still
subject to self-presentational and recall bias overestimating
adherence. However, the MMAS and the MARS 10-item scales
have been successfully validated in other studies.32–35 Further-
more, asthma control was measured by a self-administered
questionnaire. Clinical measurements of asthma control may be
more precise and objective. However, the asthma control test
(ACT) has been successfully validated in other studies consisting of
a similar population than ours and has shown to be well correlated
with baseline percent predicted forced expiratory volume.36 Thus,
the ACT may correlate well with forced expiratory volume in the
Latvian population as well. Furthermore, even though the patients
of this study were recruited from the main towns and the capital
city where the majority of the Latvian population live, the results
cannot be generalized to the overall population of Latvian asthma
patients. Moreover, it has to be mentioned that a general issue not
addressed by self-reported adherence questionnaires is inhaler
technique which is an essential part of good adherence
implementation (14). The challenges faced when using inhaled
medications can include a combination of delivery issues (e.g.,
knowing the sequence of steps required to use the inhaler
correctly, successful dose preparation, inspiratory flow rate, and in
pressurized metered-dose inhalers, dose actuation and coordina-
tion with breath inhalation); practical issues (e.g., integration and
scheduling with coexisting medications, storage, and device
cleaning); and psychosocial challenges (e.g., self-consciousness
about inhaler use in public).14, 37, 38 Thus, it may be worthwhile
developing and validating treatment adherence questionnaires
that consider these important factors. Finally, the findings of our
study may only be valid for a more severe patient population:
those patients referred to a pulmonologist and, thus, do not
necessary represent those seen in regular primary health-care.
These patients may already have some issues in regard adherence
as it is the most common cause of control.
Implications for future research, policy and practice
Moreover, future studies are needed to validate the different
asthma adherence scores, asthma control scores and other
relevant self-assessment tools in a larger sample of Latvian
asthma patients to improve their performance and utility.
CONCLUSIONS
In conclusion, none of the tested asthma treatment adherence
scales were able to predict poor asthma control in Latvian
patients. However, medication beliefs, particularly concerns and
necessity of asthma treatment were associated with poor
treatment adherence when assessed with the Morisky or 5-item
MARS scale. Therefore, we recommend to use either the MMAS or
the 5-item MARS scale in Latvian asthma patients to identify
patients with poor treatment adherence. Thus, it may be
worthwhile to assess routinely the concerns and necessity of
asthma medication in patients within the Latvian health-care
system to improve treatment adherence in that vulnerable
population group to improve treatment outcomes.
METHODS
Study population
The study population of this cross-sectional patient survey consisted of
asthma patients attending outpatient pulmonologist consultations in Riga,
Latvia during September 2013 to December 2015. Latvian patients in most
cases will receive their initial disease diagnosis and treatment initiation in a
pulmonologist practice. They get there in larger part by a referral by a
general practitioner (GP) or by direct patient contact. The majority of GPs
refer their asthma and chronic obstructive pulmonary disease patients to a
specialist at least once a year for control. The role of GPs within the Latvian
health care system is mainly to ensure that a patient follows the treatment
regime set forth by the specialist. Only patients referred by a GP to a
National Health Service (NHS) registered practice can get their medication
reimbursed by NHS. In a first step, a list of all pulmonologists from the
database of the NHS of the medical doctors that have contractual rights to
prescribe reimbursed medicines was acquired. Then, pulmonologists in
large medical centers and hospitals in Riga and in bigger towns of Latvia
were randomly selected and invited to join the study. The total number of
participating pulmonologist practices was 15. Each pulmonologist was
advised to invite his patients to join the survey. The sample size was
calculated to detect a prevalence of poor asthma control of 50% with a
margin of error of 5%, and a power of 95%. The total sample size needed
and respectively studied was 352 people. Only patients that have been
using asthma medication for at least one year were included in this study.
Assessment of main variables
A self-administered questionnaire was used to assess socio-demographic
and economic factors such as age, education, income, and sex. The
patients filled in the questionnaire right after their visit with the doctor.
Adherence to asthma medication was assessed using MMAS and two
different versions of MARS. The MMAS is a self-report tool, it was used to
assess asthma medication adherence.7 The MMAS is an eight item
questionnaire that measures medication compliance on a scale of 0–11,
with lower scores indicating greater adherence. The total MMAS score was
obtained by summing ratings for all scale items. Seven items were answered
by either yes (score = 1) or no (score = 0) responses, and one item was
assessed using 5 point Likert-type responses ranging from “usually” to “all the
time” (usually = 0; all the time = 4). The MMAS has been used across many
chronic diseases, including asthma, as a self-reported measure of adherence
to medications and has demonstrated good reliability and predictive
validity.32, 33 The long version of the MARS is a validated 10-item
questionnaire that has shown to have good internal, construct, and criterion
validity, including correlations with objective measures of adherence
(electronic monitoring and pharmacy dispensing data).8, 26 The MARS
contains items that measure intentional (“I avoid using it if I can”) and
unintentional (“I forget to use it”) nonadherence and these questions are
phrased such that nonadherence is considered common to minimize social
desirability bias. Medication use is rated on a 5-point Likert scale.34, 35 The
short version of the MARS is a five-item self-report scale for assessment of
adherent behavior that includes assessment of unintentional non-adherent
behavior (“I forgot to take them”, item 1) and intentional non-adherent
behavior (“I alter the dose”, item 2. “I stop taking them for a while”, item 3. “I
decide to miss out a dose”, item 4. “I take less than instructed”, item 5). Each
item was answered using a five-graded response scale, ranging from very
often (1) to never (5). Low scores indicate low levels of adherent behavior.36
Good asthma control was assessed using the ACT, a validated five-item
scale that reliably assesses asthma control over a recall period of 4 weeks. The
ACT consists of the following questions: “How much of the time did your
asthma keep you from getting as much done at work, school or at home?”,
“How often have you had shortness of breath?”, “How often did your asthma
symptoms wake you up at night or earlier than usual in the morning?”, “How
often have you used your rescue inhaler or nebulizer medication?” and “How
would you rate your asthma control?”.39 Each item was scaled from 1 to 5,
and by summing the response values a scale score was calculated ranging
from poor (5) to total (25) control.40, 41 ACT scores have shown to be well
correlated with baseline percent predicted forced expiratory volume.41
Medication beliefs were assessed using the five items of greatest
relevance to asthma medication adapted from the beliefs about medicines
questionnaire (BMQ), a validated tool across many disease conditions.22, 42
The specific–necessity scale contains 5 items that assess patients’ beliefs
about specific necessity to take prescribed chronic medications. Three
questions were selected from the six original items that assess patients’
beliefs about specific necessity to take prescribed chronic medications. All
belief items had Likert scale responses.
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The Brief IPQ was used to obtain information on illness perception of the
study participants. The Brief IPQ consists of eight items and a causal
question.43, 44 All of the items except the causal question are rated using a
0-to-10 response scale. Five of the items assess cognitive illness
representations: consequences (item 1), timeline (item 2), personal control
(item 3), treatment control (item 4), and identity (item 5). Two of the items
assess emotional representations: concern (item 6) and emotions (item 8).
One item assesses illness comprehensibility (item 7). Assessment of the
causal representation is by an open-ended response, which asks patients
to list the three most important causal factors in their illness (item 9).
Statistical analysis
The Statistical Package for the Social Sciences (SPSS) IBM 21.0 was used to
analyze the data. Means, standard deviations, and frequencies are presented
to describe the characteristics of the study sample. A cutoff point of >6
(MARS-5), >14 (MARS-10), >1 (MMAS) was used to define poor medical
adherence. These cut-off points were chosen according to the ones proposed
in previous studies.7, 8, 26, 34–36 A cut-off point of ≤19 for the ACT was defined
to indicate poorly controlled asthma, and scores of 20 points or more
corresponded to well-controlled asthma.40, 41 The answers of the BMQ were
dichotomized into (i) “I agree/I completely agree” and (ii) “Not sure/I disagree/I
completely disagree”. The logistic regression analysis were first conducted for
each variable alone. In the multivariate logistic analysis the outcome variable
was controlled for age, income, and educational level. The odds ratio and
respective 95% CI are presented for all models. The validity of each logistic
regression models were assessed by the Hosmer/Lemeshow test.
Ethics statement
Methods were performed in accordance with relevant guidelines and
regulations. Methods and patient consent form were approved in writing
by the P.Stradins Clinical University Hospital Development Society Ethics
committee for clinical research (original name in Latvian: P.Stradiņa Klīniskās
universitātes slimnīcas Attīstības biedrības klīniskās izpētes ētikas komiteja). A
written consent was obtained from all participants involved in the study.
Data availability
Upon request from the corresponding author.
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